Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 561.49 USD -0.3% Market Closed
Market Cap: 61.4B USD

Intrinsic Value

The intrinsic value of one REGN stock under the Base Case scenario is 625.26 USD. Compared to the current market price of 561.49 USD, Regeneron Pharmaceuticals Inc is Undervalued by 10%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

REGN Intrinsic Value
625.26 USD
Undervaluation 10%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Regeneron Pharmaceuticals Inc

REGN
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for REGN cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Regeneron Pharmaceuticals Inc
NASDAQ:REGN
US
Biotechnology
Market Cap
61.5B USD
IPO
Apr 2, 1991
US
Biotechnology
Market Cap
61.5B USD
IPO
Apr 2, 1991
Price
$false
EPS
$false
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Regeneron’s overreliance on Eylea for a significant portion of its revenue poses a major risk, especially as new anti-VEGF therapies and biosimilars could challenge its market share in retinal diseases and pressure pricing.

Bull Theses

Despite Eylea’s looming patent expiry, potential label expansions for Dupixent and newer pipeline candidates like pozelimab could diversify revenue sources and provide steady earnings growth.

Show More Less
How do you feel about REGN?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Regeneron Pharmaceuticals Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Regeneron Pharmaceuticals Inc

Current Assets 18.7B
Cash & Short-Term Investments 24.4B
Receivables 6.2B
Other Current Assets -12B
Non-Current Assets 19.1B
Long-Term Investments 8.9B
PP&E 4.6B
Intangibles 1.1B
Other Non-Current Assets 4.5B
Efficiency

Free Cash Flow Analysis
Regeneron Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Regeneron Pharmaceuticals Inc

Revenue
14.2B USD
Cost of Revenue
-1.8B USD
Gross Profit
12.4B USD
Operating Expenses
-8.1B USD
Operating Income
4.2B USD
Other Expenses
194.6m USD
Net Income
4.4B USD
Fundamental Scores

REGN Profitability Score
Profitability Due Diligence

Regeneron Pharmaceuticals Inc's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive Gross Profit
Exceptional 3-Year Average ROIC
Exceptional ROIC
73/100
Profitability
Score

Regeneron Pharmaceuticals Inc's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

REGN Solvency Score
Solvency Due Diligence

Regeneron Pharmaceuticals Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Regeneron Pharmaceuticals Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

REGN Price Targets Summary
Regeneron Pharmaceuticals Inc

Wall Street analysts forecast REGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for REGN is 952.52 USD with a low forecast of 580.75 USD and a high forecast of 1 209.6 USD.

Lowest
Price Target
580.75 USD
3% Upside
Average
Price Target
952.52 USD
70% Upside
Highest
Price Target
1 209.6 USD
115% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for REGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

REGN Insider Trading
Buy and sell transactions by insiders

REGN News

Other Videos
What is the Intrinsic Value of one REGN stock?

The intrinsic value of one REGN stock under the Base Case scenario is 625.26 USD.

Is REGN stock undervalued or overvalued?

Compared to the current market price of 561.49 USD, Regeneron Pharmaceuticals Inc is Undervalued by 10%.

Back to Top